Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401595 | 0.76 | ALDH1A1 (0.31) | CHRNB2CHRNA4 | |
| SCHEMBL4401104 | 0.74 | ALDH1A1 (0.34) | — | |
| SCHEMBL21994372 | 0.65 | CHRNB2 (0.34) | CHRNB2CHRNA4 | |
| SCHEMBL6053501 | 0.65 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL21722467 | 0.64 | LMNA (0.48) | CHRNB2CHRNA4 | |
| SCHEMBL13299292 | 0.64 | DPP8 (0.36) | CHRNB2CHRNA4 | |
| SCHEMBL4399338 | 0.62 | — | — | |
| SCHEMBL24358987 | 0.61 | CHRNB2 (0.38) | CHRNB2CHRNA4 | |
| SCHEMBL10963132 | 0.61 | CHRNB2 (0.47) | CHRNB2CHRNA4 | |
| SCHEMBL16887955 | 0.61 | CHRNB2 (0.43) | CHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2023-03-23 | — | — | US | disclosed |
| EP-3887363-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | Novartis AG (CH) | 2021-10-06 | — | — | EP | disclosed |
| WO-2020110008-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | NOVARTIS AG (CH) | 2020-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230089867-A1 | CYCLIC PENTAMER COMPOUNDS AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDER | PCSK9, PCSK7, PCSK6 | CHRNB2 1991/4885CHRNA4 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.